ClearPoint Neuro Inc(CLPT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:16 PM ET (Korea 10/31 06:16)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.21 | Insider Own | 11.27% | Shs Outstand | 32.0M | Perf Week | 16.74% |
| Market Cap | 0.34B | Forward P/E | - | EPS next Y | 21.03% | Insider Trans | -3.06% | Shs Float | 28.4M | Perf Month | -6.81% |
| Enterprise Value | 0.37B | PEG | - | EPS next Q | -0.23 | Inst Own | 45.79% | Short Float | 16.28% | Perf Quarter | -30.62% |
| Income | -0.04B | P/S | 7.52 | EPS this Y | -29.44% | Inst Trans | 1.75% | Short Ratio | 6.85 | Perf Half Y | -6.16% |
| Sales | 0.05B | P/B | 12.54 | EPS next 5Y | 1.5% | ROA | -41.75% | Short Interest | 4.63M | Perf YTD | -22% |
| Book/sh | 0.85 | P/C | 7.41 | EPS past 3/5Y | -9.9% -16.08% | ROE | -167.52% | 52W High | -57.28% ($24.98) | Perf Year | -54.94% |
| Cash/sh | 1.44 | P/FCF | - | Sales past 3/5Y | 21.62% 23.58% | ROIC | -35.86% | 52W Low | 29.02% ($8.27) | Perf 3Y | 96.86% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -46.56% | Gross Margin | 60.03% | Volatility(W/M) | 8.86% 6.16% | Perf 5Y | -36.22% |
| Dividend TTM | - | EV/Sales | 8.12 | Sales Y/Y TTM | 32.51% | Oper. Margin | -70.56% | ATR (14) | 0.74 | Perf 10Y | 120% |
| Dividend Ex-Date | - | Quick Ratio | 5.77 | EPS Q/Q | -16.22% | Profit Margin | -79.43% | RSI (14) | 48.93 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.76 | Sales Q/Q | 36.27% | SMA20 | 7.22% ($9.95) | Beta | 1.37 | Target Price | $21.5 |
| Payout | - | Debt/Eq | 2.7 | Earnings | 2026/10/28 | SMA50 | -14.68% ($12.51) | Rel Volume | 1.36 | Prev Close | $10.69 |
| Employees | 172 | LT Debt/Eq | 2.7 | EPS/Sales Surpr. | 23.81% -1.83% | SMA200 | -17.68% ($12.96) | Avg Volume(3M) | 0.68M | Price | $10.67 |
| IPO | 2012/5/21 | Option/Short | Yes/Yes | Trades | 6084 | Volume | 916,551 | Change | -0.19% |
A US medical device company that provides an MRI-guided precision neurosurgery platform along with biopharmaceutical and drug delivery services. At its core is a navigation system that uses MRI to guide intracranial procedures in real time, and the company is a niche leader that supports central nervous system drug delivery for numerous biopharma partners' clinical trials.
Over the past 1 year, on the lower side
57% below its 1-year high.
Traded more than usual. That is 136% of its average volume.
CLPT has a sound balance sheet but weak earning power
Of every $100 in sales, $70.56 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -29.4% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $752. Peers typically go for $326.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -36.2%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 45.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #69 of 142 in the industry
Based on market cap of $342M.
VMD#66 Viemed Healthcare Inc $368M PER 26.4 
CV#67 CapsoVision Inc $363M PER - 
MOBI#68 Mobia Medical Inc $352M PER - CLPT#69 ClearPoint Neuro Inc $342M PER - 
QSI#70 Quantum-Si Incorporated $320M PER - 
FAQ
What kind of company is CLPT?
CLPT belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of CLPT?
The market cap of CLPT is approximately $342M, ranking 3,502 within its sector.
What is the 52-week high and low for CLPT?
CLPT has recorded a 52-week high of $24.98 and a low of $8.27.
